Autolus Therapeutics plc (AUTL) Research

Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.

Market snapshot

Symbol
AUTL
Price
$1.51
Day change
-1.31%
Market cap
$401.9M
P/E ratio
-1.39x
52-week range
1.175-2.7
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$8.87

Peer companies

  • ADC Therapeutics S.A. (ADCT)
  • Annexon, Inc. (ANNX)
  • Aura Biosciences, Inc. (AURA)
  • Benitec Biopharma Inc. (BNTC)
  • LB Pharmaceuticals Inc Common Stock (LBRX)
  • Neumora Therapeutics, Inc. Common Stock (NMRA)
  • Quantum-Si incorporated (QSI)
  • RAPT Therapeutics, Inc. (RAPT)

Recent insider activity

  • Richardson Ryan — trade (80000 shares) on 2026-03-18
  • Piccina Cintia — trade (500000 shares) on 2026-03-18
  • Piccina Cintia — trade (148000 shares) on 2026-03-18
  • Piccina Cintia — trade (33000 shares) on 2026-03-18
  • BUTITTA CYNTHIA M — trade (10000 shares) on 2026-03-18

Open Autolus Therapeutics plc (AUTL) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.